Search - tctmd.com

Displaying 261 - 280 of 393

Sort: Relevancy | Date

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

Todd Neale

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

Todd Neale

March 12, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News ACC 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

Todd Neale

March 11, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

Presentation ACC 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Presenter: William B. White

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

Advertisement

COMPASS Approach Helps With Leg Complications in Patients With PAD

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content